Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. This Business Profile tracks the Brand Authority Index and supporting AI visibility evidence. Last analyzed August 25, 2026.
Insilico Medicine is a clinical-stage artificial intelligence (AI) driven drug discovery and development company. It leverages its proprietary Pharma.AI platform, including Biology42, Chemistry42, and Medicine42, to identify novel targets, generate new molecular structures, and accelerate the development of innovative drug candidates across various therapeutic areas.
The public category test is directional and too small to support a high-confidence rating.
Optimly has not yet published a supported competitor set for Insilico Medicine.
Brand Authority Index (BAI) tier: Contender (exact score locked for unclaimed brands)
Official website: https://insilico.com/
Last analyzed: August 25, 2026
This Business Profile is published by Optimly in the Optimly AI Brand Index, a public research dataset showing how AI systems describe brands, categories, and competitors. Optimly AI Visibility analyzes sampled buyer-intent responses, cited sources, and public brand information. The Brand Authority Index summarizes answer presence, narrative accuracy, and owned citations where sufficient evidence is available.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile